MA52888A - Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques - Google Patents

Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques

Info

Publication number
MA52888A
MA52888A MA052888A MA52888A MA52888A MA 52888 A MA52888 A MA 52888A MA 052888 A MA052888 A MA 052888A MA 52888 A MA52888 A MA 52888A MA 52888 A MA52888 A MA 52888A
Authority
MA
Morocco
Prior art keywords
therapeutic agents
benzene sulfonamide
sulfonamide compounds
compounds
benzene
Prior art date
Application number
MA052888A
Other languages
English (en)
Inventor
Kristen Nicole Burford
Thilo Focken
Verner Alexander Lofstrand
Michael Scott Wilson
Alla Yurevna Zenova
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA52888A publication Critical patent/MA52888A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052888A 2018-06-13 2019-06-13 Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques MA52888A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862684436P 2018-06-13 2018-06-13

Publications (1)

Publication Number Publication Date
MA52888A true MA52888A (fr) 2021-04-21

Family

ID=67138087

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052888A MA52888A (fr) 2018-06-13 2019-06-13 Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques

Country Status (23)

Country Link
US (2) US10745392B2 (fr)
EP (1) EP3807281A1 (fr)
JP (3) JP7371029B2 (fr)
KR (1) KR102833674B1 (fr)
CN (1) CN112262142B (fr)
AU (1) AU2019285184B2 (fr)
BR (1) BR112020024729A2 (fr)
CA (1) CA3103600A1 (fr)
CL (1) CL2020003197A1 (fr)
CR (1) CR20200613A (fr)
EA (1) EA202092719A1 (fr)
EC (1) ECSP20079861A (fr)
IL (1) IL278949B2 (fr)
JO (1) JOP20200304A1 (fr)
MA (1) MA52888A (fr)
MX (1) MX2020013317A (fr)
NI (1) NI202000098A (fr)
PE (1) PE20211389A1 (fr)
PH (1) PH12020552111A1 (fr)
SA (1) SA520420768B1 (fr)
SG (1) SG11202011862PA (fr)
UA (1) UA127024C2 (fr)
WO (1) WO2019241533A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201468A1 (fr) * 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Composés benzènesulfonamides et leur utilisation en tant qu'agents thérapeutiques
EP3551626B1 (fr) 2016-12-09 2023-10-25 Xenon Pharmaceuticals Inc. Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
AU2019285184B2 (en) * 2018-06-13 2023-11-16 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
EP4655291A2 (fr) * 2023-01-26 2025-12-03 Merck Sharp & Dohme LLC Composés d'indazole sulfonamide n-substitués à activité sélective dans le contexte de canaux sodiques voltage-dépendants
WO2026165348A1 (fr) 2025-01-31 2026-08-06 Neurocrine Biosciences, Inc. 4-((2-((7-azabicyclo[2.2.1]heptan-7-yl)méthyl)-6-fluorobenzyl)amino)-2,3-difluoro-n-(thiazol-4-yl)benzènesulfonamide destiné à être utilisé dans le traitement de troubles épileptiques

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
CA2349832A1 (fr) 1999-01-13 2000-07-20 Warner-Lambert Company Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek
DE19907385A1 (de) 1999-02-20 2000-08-24 Boehringer Ingelheim Pharma Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine
ATE250932T1 (de) 1999-07-16 2003-10-15 Warner Lambert Co Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
GB9928568D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Chemical compounds
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
CA2744893A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Derives d'arylcarbonyle servant d'activateurs de glucokinase
JP2005162726A (ja) 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
WO2004092123A2 (fr) 2003-04-10 2004-10-28 Microbia, Inc. Inhibiteurs d'invasion fongique
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
CA2531418A1 (fr) 2003-07-08 2005-01-20 Novartis Ag Composes benzenesulfonylamino, et compositions pharmaceutiques contenant ces composes
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
WO2006066109A2 (fr) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Inhibiteurs des hydroxysteroides deshydrogenases
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2007039171A1 (fr) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzène sulfonamides, procédés pour leur préparation et leur utilisation en tant que substances pharmaceutiques
WO2007075895A2 (fr) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Derives heterocycliques utilises comme modulateurs de canaux ioniques
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
US8853250B2 (en) 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
JP5460589B2 (ja) * 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
WO2009013171A2 (fr) 2007-07-24 2009-01-29 F. Hoffmann-La Roche Ag Composés antiviraux hétérocycliques
WO2009099177A1 (fr) 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. Dérivé d'amino-imidazole
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
EP2307412A2 (fr) 2008-07-01 2011-04-13 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques en tant que modulateurs des canaux ioniques
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
CA2747419C (fr) 2009-01-12 2014-07-08 Icagen, Inc. Derives sulfonamides
WO2012004743A1 (fr) 2010-07-09 2012-01-12 Pfizer Limited Benzènesulfonamides utiles en tant qu'inhibiteurs des canaux sodiques
BR112013003864B1 (pt) 2010-08-20 2021-08-31 Hutchison Medipharma Limited Compostos de pirrolpirimidina, composição e uso dos mesmos
AU2012296529A1 (en) 2011-08-17 2014-02-20 Amgen Inc. Heteroaryl sodium channel inhibitors
AU2012328561A1 (en) 2011-10-28 2014-04-17 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
MX2014005304A (es) 2011-10-31 2015-03-20 Xenon Pharmaceuticals Inc Biaril eter sulfonamidas y su uso como agentes terapeuticos.
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
WO2013122897A1 (fr) 2012-02-13 2013-08-22 Amgen Inc. Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
CA2874621A1 (fr) 2012-05-22 2013-11-28 Genentech, Inc. Benzamides n-substitues et leur utilisation dans le traitement de la douleur
US9376429B2 (en) 2012-10-15 2016-06-28 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
JP2015535251A (ja) 2012-10-26 2015-12-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有するベンゾオキサゾリノン化合物
AU2013334664A1 (en) 2012-10-26 2015-05-07 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
WO2015035278A1 (fr) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company Modulateurs de rorγ
CN105611923B (zh) 2013-09-10 2019-08-23 卓莫赛尔公司 用于治疗疼痛和糖尿病的钠通道调节剂
JP6383418B2 (ja) 2013-11-27 2018-08-29 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
WO2015077905A1 (fr) 2013-11-29 2015-06-04 Merck Sharp & Dohme Corp. Composés de benzènesulfonamide à substitution bicycloamine ayant une activité sélective dans les canaux sodiques sensibles à la tension
CA2934473C (fr) 2013-12-23 2019-08-20 Purdue Pharma L.P. Indazoles et leur utilisation
CN106795149B (zh) 2015-05-05 2019-09-24 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
BR112018012408A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica?
US10442778B2 (en) 2016-03-22 2019-10-15 Merck Sharp & Dohme Corp. N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels
WO2017201468A1 (fr) * 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Composés benzènesulfonamides et leur utilisation en tant qu'agents thérapeutiques
ES2897998T3 (es) 2016-10-27 2022-03-03 Bristol Myers Squibb Co Inhibidores de la acilsulfonamida del NaV1.7
US10968210B2 (en) * 2016-11-17 2021-04-06 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3551626B1 (fr) 2016-12-09 2023-10-25 Xenon Pharmaceuticals Inc. Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
AU2019285184B2 (en) * 2018-06-13 2023-11-16 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

Also Published As

Publication number Publication date
PE20211389A1 (es) 2021-07-27
MX2020013317A (es) 2021-04-13
IL278949A (en) 2021-01-31
KR102833674B1 (ko) 2025-07-14
US11325902B2 (en) 2022-05-10
PH12020552111A1 (en) 2021-08-02
CR20200613A (es) 2021-06-10
EP3807281A1 (fr) 2021-04-21
CN112262142A (zh) 2021-01-22
CL2020003197A1 (es) 2021-04-30
JP2021528387A (ja) 2021-10-21
JP7371029B2 (ja) 2023-10-30
BR112020024729A2 (pt) 2021-03-23
JOP20200304A1 (ar) 2020-11-25
KR20210019507A (ko) 2021-02-22
ECSP20079861A (es) 2021-03-31
US10745392B2 (en) 2020-08-18
UA127024C2 (uk) 2023-03-15
EA202092719A1 (ru) 2021-03-16
NI202000098A (es) 2021-05-28
SG11202011862PA (en) 2020-12-30
AU2019285184B2 (en) 2023-11-16
AU2019285184A1 (en) 2021-01-28
SA520420768B1 (ar) 2022-08-30
CA3103600A1 (fr) 2019-12-19
US20200361927A1 (en) 2020-11-19
IL278949B2 (en) 2024-08-01
WO2019241533A1 (fr) 2019-12-19
US20190382398A1 (en) 2019-12-19
IL278949B1 (en) 2024-04-01
CN112262142B (zh) 2023-11-14
JP2025128218A (ja) 2025-09-02
JP2023138672A (ja) 2023-10-02

Similar Documents

Publication Publication Date Title
MA48583A (fr) Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
MA53489A (fr) Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques
EP3814567A4 (fr) Appareil d'entretien de vêtements
EP3717462A4 (fr) Composés de sulfonamide et leur utilisation
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
EP3886879A4 (fr) Plaquettes en tant qu'agents de livraison
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
EP3883576A4 (fr) Composés amino-triazolopyrimidine et amino-triazolopyrazine substitués utilisés en tant qu'antagonistes de récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
MA45375A (fr) Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA49017A (fr) Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
EP3860449A4 (fr) Agencement d'électrodes
EP3463315A4 (fr) Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale
MA44734A (fr) Composés et compositions destinés au traitement d'états associés à une activité de nlrp
EP3250035A4 (fr) Composés et leur utilisation en tant qu'inhibiteurs de bace1
EP3621973A4 (fr) Composés pour la prévention et le traitement de maladies et leur utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
MA56183A (fr) Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MA52244A (fr) Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
EP3892621A4 (fr) Composés d'halogénoallylamine et leur utilisation
EP3334719A4 (fr) Benzimidazoles substitués, préparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques
MA53488A (fr) Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
MA53086A (fr) Thiophènecarboxamides et analogues substitués utilisés en tant qu'agents antibactériens
EP3917380C0 (fr) Évaluation de la progression de la maladie de huntington